MX2022001864A - Construcciones de arni para inhibir la expresión de slc30a8 y métodos de uso de las mismas. - Google Patents
Construcciones de arni para inhibir la expresión de slc30a8 y métodos de uso de las mismas.Info
- Publication number
- MX2022001864A MX2022001864A MX2022001864A MX2022001864A MX2022001864A MX 2022001864 A MX2022001864 A MX 2022001864A MX 2022001864 A MX2022001864 A MX 2022001864A MX 2022001864 A MX2022001864 A MX 2022001864A MX 2022001864 A MX2022001864 A MX 2022001864A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- rnai constructs
- slc30a8
- expression
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a construcciones de ARNi para reducir la expresión del gen de SLC30A8. También se describen métodos de uso de tales construcciones de ARNi para tratar o prevenir una enfermedad, tal como prediabetes o diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962886269P | 2019-08-13 | 2019-08-13 | |
PCT/US2020/046222 WO2021030613A1 (en) | 2019-08-13 | 2020-08-13 | Rnai constructs for inhibiting slc30a8 expression and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001864A true MX2022001864A (es) | 2022-05-30 |
Family
ID=72243237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001864A MX2022001864A (es) | 2019-08-13 | 2020-08-13 | Construcciones de arni para inhibir la expresión de slc30a8 y métodos de uso de las mismas. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220340911A1 (es) |
EP (1) | EP4013871A1 (es) |
JP (1) | JP2022544238A (es) |
AU (1) | AU2020329286A1 (es) |
CA (1) | CA3150758A1 (es) |
MX (1) | MX2022001864A (es) |
WO (1) | WO2021030613A1 (es) |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
EP1588761A3 (en) | 1991-11-22 | 2005-11-23 | Affymetrix, Inc. | Method of forming arrays of polymers |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1549352A4 (en) | 2002-05-06 | 2005-07-27 | Nucleonics Inc | METHOD OF DISTRIBUTING NUCLEIC ACIDS |
US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
AU2014284152B2 (en) | 2013-06-21 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
-
2020
- 2020-08-13 US US17/634,708 patent/US20220340911A1/en active Pending
- 2020-08-13 CA CA3150758A patent/CA3150758A1/en active Pending
- 2020-08-13 AU AU2020329286A patent/AU2020329286A1/en active Pending
- 2020-08-13 JP JP2022508526A patent/JP2022544238A/ja active Pending
- 2020-08-13 WO PCT/US2020/046222 patent/WO2021030613A1/en unknown
- 2020-08-13 MX MX2022001864A patent/MX2022001864A/es unknown
- 2020-08-13 EP EP20761977.6A patent/EP4013871A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4013871A1 (en) | 2022-06-22 |
JP2022544238A (ja) | 2022-10-17 |
WO2021030613A1 (en) | 2021-02-18 |
CA3150758A1 (en) | 2021-02-18 |
US20220340911A1 (en) | 2022-10-27 |
AU2020329286A1 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550833A1 (en) | Rnai constructs for inhibiting pnpla3 expression | |
AU2019268063A1 (en) | Compositions for modulating sod-1 expression | |
ZA202108348B (en) | Angiotensinogen (agt) irna compositions and methods of use thereof | |
MX2021006053A (es) | Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas. | |
PH12014501106A1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
PH12015501953A1 (en) | Substituted nucleotide analogs | |
PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
MX2010005651A (es) | Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento. | |
MX2019002271A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
MX2021006784A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos. | |
PH12020550195A1 (en) | Use of p38 inhibitors to reduce expression of dux4 | |
MX2021014465A (es) | Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas. | |
TR201818825T4 (tr) | Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar | |
MX2022005692A (es) | Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt). | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
MX2022015169A (es) | Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos. | |
NZ740817A (en) | Pcna inhibitors | |
EP4219715A3 (en) | Stabilized cebpa sarna compositions and methods of use | |
MX2022001864A (es) | Construcciones de arni para inhibir la expresión de slc30a8 y métodos de uso de las mismas. | |
WO2020104649A3 (en) | Novel rna compositions and methods for inhibiting angptl8 | |
EA202090857A1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ p38 ДЛЯ СНИЖЕНИЯ ЭКСПРЕССИИ DUX4 | |
NZ779762A (en) | Pcna inhibitors |